194 related articles for article (PubMed ID: 9406236)
1. Selenium and the thioredoxin redox system: effects on cell growth and death.
Powis G; Gasdaska JR; Gasdaska PY; Berggren M; Kirkpatrick DL; Engman L; Cotgreave IA; Angulo M; Baker A
Oncol Res; 1997; 9(6-7):303-12. PubMed ID: 9406236
[TBL] [Abstract][Full Text] [Related]
2. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents.
Engman L; Cotgreave I; Angulo M; Taylor CW; Paine-Murrieta GD; Powis G
Anticancer Res; 1997; 17(6D):4599-605. PubMed ID: 9494575
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium.
Gallegos A; Berggren M; Gasdaska JR; Powis G
Cancer Res; 1997 Nov; 57(21):4965-70. PubMed ID: 9354464
[TBL] [Abstract][Full Text] [Related]
4. Cellular thioredoxin reductase activity is regulated by selenium.
Berggren M; Gallegos A; Gasdaska J; Powis G
Anticancer Res; 1997; 17(5A):3377-80. PubMed ID: 9413175
[TBL] [Abstract][Full Text] [Related]
5. The thioredoxin/thioredoxin reductase redox system and control of cell growth.
Powis G; Oblong JE; Gasdaska PY; Berggren M; Hill SR; Kirkpatrick DL
Oncol Res; 1994; 6(10-11):539-44. PubMed ID: 7620223
[TBL] [Abstract][Full Text] [Related]
6. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism.
Gasdaska JR; Berggren M; Powis G
Cell Growth Differ; 1995 Dec; 6(12):1643-50. PubMed ID: 9019170
[TBL] [Abstract][Full Text] [Related]
7. A redox-inactive thioredoxin reduces growth and enhances apoptosis in WEHI7.2 cells.
Freemerman AJ; Powis G
Biochem Biophys Res Commun; 2000 Jul; 274(1):136-41. PubMed ID: 10903908
[TBL] [Abstract][Full Text] [Related]
8. Thioredoxin redox control of cell growth and death and the effects of inhibitors.
Powis G; Kirkpatrick DL; Angulo M; Baker A
Chem Biol Interact; 1998 Apr; 111-112():23-34. PubMed ID: 9679540
[TBL] [Abstract][Full Text] [Related]
9. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia.
Berggren M; Gallegos A; Gasdaska JR; Gasdaska PY; Warneke J; Powis G
Anticancer Res; 1996; 16(6B):3459-66. PubMed ID: 9042207
[TBL] [Abstract][Full Text] [Related]
10. Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells.
Gallegos A; Gasdaska JR; Taylor CW; Paine-Murrieta GD; Goodman D; Gasdaska PY; Berggren M; Briehl MM; Powis G
Cancer Res; 1996 Dec; 56(24):5765-70. PubMed ID: 8971189
[TBL] [Abstract][Full Text] [Related]
11. Selenite-induced apoptosis in doxorubicin-resistant cells and effects on the thioredoxin system.
Jönsson-Videsäter K; Björkhem-Bergman L; Hossain A; Söderberg A; Eriksson LC; Paul C; Rosén A; Björnstedt M
Biochem Pharmacol; 2004 Feb; 67(3):513-22. PubMed ID: 15037203
[TBL] [Abstract][Full Text] [Related]
12. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo.
Baker A; Payne CM; Briehl MM; Powis G
Cancer Res; 1997 Nov; 57(22):5162-7. PubMed ID: 9371519
[TBL] [Abstract][Full Text] [Related]
13. Calcium-dependent oxidation of thioredoxin during cellular growth initiation.
Gitler C; Zarmi B; Kalef E; Meller R; Zor U; Goldman R
Biochem Biophys Res Commun; 2002 Jan; 290(2):624-8. PubMed ID: 11785944
[TBL] [Abstract][Full Text] [Related]
14. Redox active disulfides: the thioredoxin system as a drug target.
Kirkpatrick DL; Ehrmantraut G; Stettner S; Kunkel M; Powis G
Oncol Res; 1997; 9(6-7):351-6. PubMed ID: 9406241
[TBL] [Abstract][Full Text] [Related]
15. Modulation of p53 dependent gene expression and cell death through thioredoxin-thioredoxin reductase by the Interferon-Retinoid combination.
Hu J; Ma X; Lindner DJ; Karra S; Hofmann ER; Reddy SP; Kalvakolanu DV
Oncogene; 2001 Jul; 20(31):4235-48. PubMed ID: 11464290
[TBL] [Abstract][Full Text] [Related]
16. Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation.
Karimpour S; Lou J; Lin LL; Rene LM; Lagunas L; Ma X; Karra S; Bradbury CM; Markovina S; Goswami PC; Spitz DR; Hirota K; Kalvakolanu DV; Yodoi J; Gius D
Oncogene; 2002 Sep; 21(41):6317-27. PubMed ID: 12214272
[TBL] [Abstract][Full Text] [Related]
17. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase.
Ganther HE
Carcinogenesis; 1999 Sep; 20(9):1657-66. PubMed ID: 10469608
[TBL] [Abstract][Full Text] [Related]
18. Thioredoxin and thioredoxin reductase: current research with special reference to human disease.
Holmgren A; Lu J
Biochem Biophys Res Commun; 2010 May; 396(1):120-4. PubMed ID: 20494123
[TBL] [Abstract][Full Text] [Related]
19. Mammalian thioredoxin reductase: oxidation of the C-terminal cysteine/selenocysteine active site forms a thioselenide, and replacement of selenium with sulfur markedly reduces catalytic activity.
Lee SR; Bar-Noy S; Kwon J; Levine RL; Stadtman TC; Rhee SG
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2521-6. PubMed ID: 10688911
[TBL] [Abstract][Full Text] [Related]
20. Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs.
Kunkel MW; Kirkpatrick DL; Johnson JI; Powis G
Anticancer Drug Des; 1997 Dec; 12(8):659-70. PubMed ID: 9448705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
